维格列汀:修订间差异
删除的内容 添加的内容
(未显示2个用户的2个中间版本) | |||
第1行: | 第1行: | ||
{{medical}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
第55行: | 第56行: | ||
| synonyms = <small>(2''S'')-1-<nowiki/>{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile</small> |
| synonyms = <small>(2''S'')-1-<nowiki/>{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile</small> |
||
}} |
}} |
||
'''維格列汀({{lang-en|Vildagliptin}} |
'''維格列汀'''({{lang-en|Vildagliptin}}),商品名為'''高糖優適''',是一種[[二肽基肽酶-4抑制劑]]類口服[[抗糖尿病藥]],用來治療[[第2型糖尿病]]。<ref name=ahren/><ref name=mentlein/><ref name=mentlein>{{cite journal | last1 = Mentlein | first1 = R | last2 = Gallwitz | first2 = B | last3 = Schmidt | first3 = WE | title = Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum | journal = European journal of biochemistry / FEBS | volume = 214 | issue = 3 | pages = 829–35 | year = 1993 | pmid = 8100523 | doi=10.1111/j.1432-1033.1993.tb17986.x}}</ref><ref name=ahren>{{cite journal | doi = 10.1210/jc.2003-031907 | last1 = Ahrén | first1 = B | last2 = Landin-Olsson | first2 = M | last3 = Jansson | first3 = PA | last4 = Svensson | first4 = M | last5 = Holmes | first5 = D | last6 = Schweizer | first6 = A | title = Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes | url = http://jcem.endojournals.org/cgi/content/full/89/5/2078 | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 89 | issue = 5 | pages = 2078–84 | year = 2004 | pmid = 15126524 | access-date = 2015-08-30 | archive-date = 2011-05-16 | archive-url = https://web.archive.org/web/20110516204917/http://jcem.endojournals.org/cgi/content/full/89/5/2078 | dead-url = no }}</ref> |
||
维格列汀是唯一一种无论在高血糖或低血糖时都可以抑制[[胰高血糖素]]的物质。 |
维格列汀是唯一一种无论在高血糖或低血糖时都可以抑制[[胰高血糖素]]的物质。 |
2022年7月17日 (日) 00:53的最新版本
臨床資料 | |
---|---|
商品名 | Galvus |
其他名稱 | (2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile |
AHFS/Drugs.com | 国际药品名称 |
核准狀況 | |
懷孕分級 |
|
给药途径 | 口服 |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 85% |
血漿蛋白結合率 | 9.3% |
药物代谢 | 主要水解为非活性代谢物; CYP450没有明显参与 |
生物半衰期 | 2-3小时 |
排泄途徑 | 肾脏 |
识别信息 | |
| |
CAS号 | 274901-16-5 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.712 |
化学信息 | |
化学式 | C17H25N3O2 |
摩尔质量 | 303.399 g/mol |
3D模型(JSmol) | |
| |
|
維格列汀(英語:Vildagliptin),商品名為高糖優適,是一種二肽基肽酶-4抑制劑類口服抗糖尿病藥,用來治療第2型糖尿病。[2][3][3][2]
维格列汀是唯一一种无论在高血糖或低血糖时都可以抑制胰高血糖素的物质。
引用[编辑]
- ^ WHO International Working Group for Drug Statistics Methodology. ATC/DDD Classification (FINAL): New ATC 5th level codes. WHO Collaborating Centre for Drug Statistics Methodology. August 27, 2008 [2008-09-05]. (原始内容存档于2008年5月6日).
- ^ 2.0 2.1 Ahrén, B; Landin-Olsson, M; Jansson, PA; Svensson, M; Holmes, D; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2004, 89 (5): 2078–84 [2015-08-30]. PMID 15126524. doi:10.1210/jc.2003-031907. (原始内容存档于2011-05-16).
- ^ 3.0 3.1 Mentlein, R; Gallwitz, B; Schmidt, WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European journal of biochemistry / FEBS. 1993, 214 (3): 829–35. PMID 8100523. doi:10.1111/j.1432-1033.1993.tb17986.x.
|
|